Serum Citrate in Diagnosis and Follow-up for Glaucoma

NCT ID: NCT00804063

Last Updated: 2015-01-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-12-31

Study Completion Date

2013-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Glaucoma might be a mitochondria associated disease. Since citrate is a major component in mitochondrial metabolism its determination in blood might serve as a biomarker.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

glaucoma patients

drawing blood sample

Intervention Type PROCEDURE

fasting blood sample

2

non-glaucoma controls

drawing blood sample

Intervention Type PROCEDURE

fasting blood sample

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

drawing blood sample

fasting blood sample

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age\> 18 years
* glaucoma

Exclusion Criteria

* Active ocular inflammation
* Ocular Hypertension
* Nephropathy
* Alcohol-, Drug abuse
* Mitochondriopathy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kantonsspital Baselland Bruderholz

OTHER

Sponsor Role collaborator

University Hospital, Basel, Switzerland

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David Goldblum, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Basel, Switzerland

Josef Flammer, MD

Role: STUDY_CHAIR

University Hospital, Basel, Switzerland

Selim Orguel, MD

Role: STUDY_DIRECTOR

University Hospital, Basel, Switzerland

Stephan Fraenkl, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Basel, Switzerland

Fabrizio Branca, MD

Role: PRINCIPAL_INVESTIGATOR

University Basel

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Basel

Basel, Canton of Basel-City, Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EK 325/08

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Nicotinamide and Glaucoma
NCT05916066 COMPLETED NA